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Troubling news from Asia about treating enteric fever: 
a coming storm
In The Lancet Infectious Diseases, Amit Arjyal and 
colleagues1 report the results from their randomised 
clinical trial comparing gatiﬂ oxacin with ceftriaxone for 
patients with uncomplicated enteric fever in Nepal. Their 
two main ﬁ ndings are sobering. First, they suggest that 
ﬂ uoroquinolones should no longer be recommended 
as front-line empirical treatment for individuals with 
enteric fever in Nepal. Second, a large proportion of 
individuals in Nepal who are syndromically characterised 
as having uncomplicated enteric fever probably have an 
alternative diagnosis.
Brieﬂ y, the investigators did a trial through two hospitals 
in Kathmandu valley, Nepal, enrolling 239 individuals 
with suspected enteric fever and randomly assigning 
them to either gatiﬂ oxacin (n=120) or ceftriaxone 
(n=119). 116 patients had microbiologically conﬁ rmed 
disease—either Salmonella enterica serovar Typhi 
(the cause of typhoid fever) or S enterica serovar 
Paratyphi A (a prevalent cause of paratyphoid fever 
in Nepal). Analysis of the modiﬁ ed intention-to-treat 
population showed that treatment failure did not diﬀ er 
between patients treated with gatiﬂ oxacin (18 [15%]) 
versus ceftriaxone (19 [16%]; hazard ratio [HR] 1·04 
[95% CI 0·55–1·98]; p=0·91). However, when the cohorts 
were separated into patients with microbiologically 
conﬁ rmed enteric fever versus those who were blood-
culture negative, substantial diﬀ erences emerged. In 
the blood culture-conﬁ rmed population, 16 (26%) of 
62 patients who received gatiﬂ oxacin failed treatment, 
versus four (7%) of 54 who received ceftriaxone 
(HR 0·24 [95% CI 0·08–0·73]; p=0·01). However, in the 
culture-negative subgroup, only two (3%) of 58 patients 
who received gatiﬂ oxacin failed treatment, versus 
15 (23%) of 65 who received ceftriaxone. What do these 
results mean?
First, some context: multidrug-resistant strains of 
S Typhi are now globally prevalent.2 In this reality, 
three classes of drugs have become the cornerstones 
of treatment for enteric fever: ﬂ uoroquinolones, 
third-generation cephalosporins, and macrolides. 
Despite a stepwise progression in both the degree and 
spread of ﬂ uoroquinolone resistance for S Typhi, until 
2010–11 patients still seemed to clinically respond to 
the fourth-generation gatiﬂ oxacin.3,4 However, the 
results from Arjyal and colleagues1 suggest that even 
advanced ﬂ uoroquinolones might now be ineﬀ ective. 
Indeed, their trial was terminated early because of the 
high clinical failure rate of gatiﬂ oxacin in patients with 
culture-conﬁ rmed enteric fever caused by S Typhi. The 
fact that ﬂ uoroquinolone-resistant strains of S Typhi 
might actually have a selective advantage over wild-type 
strains also strongly suggests that such highly-resistant 
strains might rapidly globally spread.5
The results from Arjyal and colleagues’ study also 
suggest that simply switching to another class of drug, 
such as third-generation cephalosporins, would not 
be a wholly correct solution, at least in Nepal, because 
individuals who were culture-negative for enteric fever 
in this study and received ceftriaxone actually fared 
signiﬁ cantly worse than those receiving gatiﬂ oxacin. 
One reason for these ﬁ ndings is that a large percentage 
of individuals in this study who were syndromically 
categorised as having enteric fever probably had 
instead an infection caused by other pathogens that 
were not aﬀ ected by ceftriaxone (but were susceptible 
to ﬂ uoroquinolones). Indeed, in other studies, 6,7 this 
same group of investigators has shown that a large 
proportion (5%–20%) of non-speciﬁ c febrile illness in 
Nepal is murine typhus. 
Thus, the study by Arjyal and colleagues is important 
for several reasons. First, it strongly suggests that time 
is running out for eﬀ ective antimicrobial drugs for 
enteric fever, and that the widespread inappropriate 
use of antimicrobial agents must be curtailed. With the 
loss of ﬂ uoroquinolones, treatment will be reduced to 
a few advanced antimicrobials that need to be given 
intravenously, oral agents such as ceﬁ xime (that has 
been associated with a high occurrence of clinical relapse 
in initial ﬁ eld studies),8 and azithromycin (the so-called 
back-to-the-wall option). Soberingly, salmonella strains 
that have acquired resistance to extended spectrum 
beta-lactamases and carbepenemases will probably soon 
spread globally, further curtailing these already scarce 
options. Then, when azithromycin-resistant strains 
emerge (and they will), options will simply no longer 
exist. Second, the ﬁ ndings underline that diagnostically, 
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In The Lancet Infectious Diseases Robert Heyderman 
and colleagues1 report on a phase 2 clinical trial 
comparing the safety and immunogenicity of a 
trivalent glycoconjugate vaccine directed against 
group B streptococci (GBS) in pregnant HIV-infected 
and uninfected women in Malawi and South Africa. In 
my opinion the most important message of this Article 
is that ﬁ nally—more than 40 years after the magnitude 
of neonatal GBS disease was ﬁ rst recognised—a 
promising vaccine against GBS is studied in the target 
group of pregnant women; and in particular, it is 
tested in women with HIV in sub-Saharan Africa where 
the disease burden is supposed to be highest. 
During the early 1970s, the attention to GBS 
changed greatly when three hallmark manuscripts 
reported simultaneously that GBS had emerged as the 
leading pathogen in neonatal sepsis in the USA.2 At 
present, GBS is one of the most important pathogens 
worldwide, leading to neonatal sepsis, death, and 
disability.3 In sub-Saharan Africa—and particularly 
in pregnant women with HIV—the risk for invasive 
neonatal GBS disease is supposed to be many times 
higher than in the USA and Europe.
In the 1990s, a ﬁ rst milestone towards successful 
containment was reached when consensus recom-
mendations for the prevention of neonatal 
GBS disease were issued by the key professional 
organisations in the USA, the American College of 
Obstetricians and the American Academy of Pediatrics, 
together with the Centers for Disease Control and 
Prevention. In brief, the recommendations were 
to screen pregnant women for GBS colonisation 
(screening-based approach), and to give intrapartum 
antibiotic prophylaxis to women positive for GBS or to 
women with speciﬁ c risk factors (risk-based approach). 
Consequently, from 1993 to 1998, the incidence of 
neonatal early onset GBS disease (which is deﬁ ned as 
occurring between days 0 to 7 postpartum) decreased 
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confusion prevails when patients receive clinical care 
in resource-limited areas with non-speciﬁ c but serious 
febrile illnesses. Sensitive, accurate, inexpensive, and 
point-of-care diagnostic assays are needed that can 
distinguish enteric fever from other common non-
speciﬁ c febrile illnesses that need individualised treat-
ment, including invasive non-typhoidal salmonellosis, 
rickettsiosis, leptospirosis, malaria, and arboviral and 
other viral infections.9 Unfortunately, many decades 
might pass until the most impoverished members of our 
global community live in the conditions that mitigate 
their risk of acquiring such diseases. In the meantime, 
crucial methods that enhance our ability to care for 
these patients are either absent or have been lost. Now 
is the time to initiate coordinated control programmes 
against typhoid before the storm hits—we have been 
warned.
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